Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. - Wikidata - awgldk - TriplyDB

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

http://www.wikidata.org/entity/Q35134684

about

Current and emerging azole antifungal agents Virulence-Associated Enzymes of Cryptococcus neoformans Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes Global transcriptome profile of Cryptococcus neoformans during exposure to hydrogen peroxide induced oxidative stress Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.Heteroresistance of Cryptococcus gattii to fluconazole.Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.Regulatory circuitry governing fungal development, drug resistance, and disease.Drug strategies targeting CYP51 in neglected tropical diseases Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Fluconazole-Induced Ploidy Change in Cryptococcus neoformans Results from the Uncoupling of Cell Growth and Nuclear Division.Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance Efflux-mediated antifungal drug resistance.Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

P2860

Q24550733-19C3BABA-FD7B-4675-8C2E-EE3690E0942F Q26785005-CCE7890A-FB20-44AE-B8EB-37307D784A65 Q27315103-3C5812FD-2DBE-49D5-89C6-E50F62043052 Q28485327-FFA8698A-80AD-4361-ADAF-F0593E0D1C35 Q33721804-EE1E5A97-C020-48B9-B935-47CC35C8E804 Q33876577-33F71A74-81DA-45B6-976F-35BAFC473FFD Q33977302-240B57E3-F2CE-4467-82D3-1642715CA517 Q34190284-137EDBA0-B8C1-4538-B2EA-0FB7785C4EE9 Q34622554-8F54CF96-6E87-43C4-A222-16544B059CDB Q35806201-945C69C3-6338-43DE-893C-9C8CF362D3E8 Q35854764-611D1A3D-911E-47F9-AA14-81B226D297AE Q36364064-BB720E04-34B8-43BF-985F-73FE0A51DEEA Q36409929-8558615F-FE09-41B4-9942-9BD3868F3FA1 Q37122826-3A244D77-E6DE-427B-9330-AD0C4149720F Q37156645-76D77DFA-9A9D-47FD-A4BA-6B1E44354262 Q37247728-CDB41013-AC72-4C9B-A4DE-7609B1C28F58 Q39493735-42024512-8413-4963-B433-CCC420D17189 Q39558473-0038F419-217A-4173-B0AD-4B809009217F Q39670853-AE7249E4-ABE8-4748-B667-9DDA0B68DC8E Q39732812-36648C80-89AF-40F2-BA4E-A06ACD50E3F9 Q40130606-CE0BEED6-3CC8-4CB7-87BF-5ACF6CF7DCED

P2860

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

http://www.wikidata.org/entity/Q35134684

description

1997 nî lūn-bûn

@nan

1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

@ast

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

@en

type

label

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

@ast

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

@en

prefLabel

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

@ast

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

@en

P1433

Q35134684-F1BA87FD-2F5F-49D1-9F7D-140827356929

P1476

Q35134684-8A8A4CDA-7B43-4C48-A79F-6050E4CC9AAC

P2093

Q35134684-58EC8FCB-3821-4ED7-9962-7BEFC59CAD4C

Q35134684-7DCE610F-6BD1-47DC-B937-612F0C5CC3B2

Q35134684-C0508BDA-93B8-422E-8384-6250CC47DBEB

Q35134684-DB0CC022-4300-4240-9E20-C0690797B994

Q35134684-ECC73273-7BA0-4461-8A8D-6918405D9DC6

P2860

Q35134684-0B9FA0E9-6DAB-40C2-8488-2F70BBFDB833

Q35134684-0D082BED-0586-4E4F-96E5-DEF27851403D

Q35134684-2516725E-D306-43D9-B1B0-9CAE7BC4CC73

Q35134684-26EA7530-1470-4190-B2F1-118CAC20DCA3

Q35134684-32763761-A601-4F5A-B038-480D0282C9D9

Q35134684-385DB542-6B78-4DA7-A22B-6E72C4DC083C

Q35134684-4A3A6566-9E82-4971-94B6-8FA2B221D788

Q35134684-8171AA3A-30FD-490C-95AF-614078C42457

Q35134684-AC96F9CF-32E0-4937-92F7-854B9B739CF2

Q35134684-C0E12944-A4F5-47FF-8B1B-12D147CA84F5

P304

Q35134684-A03C8205-F8B7-4D40-BE9E-ADDD86BA2F64

P31

Q35134684-5CC9D9AB-7D91-45A0-B2DC-450B57D3B88C

P356

Q35134684-71E20C7A-166B-40FF-B2EC-D16E2FF35EAD

P407

Q35134684-B1667391-94C1-494C-93A9-EA08CCEDEC35

P433

Q35134684-9862E9E5-808B-44E0-A627-BF337C52EDD5

P478

Q35134684-DCC0FCF4-FECD-4982-8C77-260482F6EF1E

P577

Q35134684-2827C6EC-3218-45DF-85A1-510D84B7258E

P698

Q35134684-28F82E5A-656F-420F-A95B-A6C858DA7F30

P932

Q35134684-B7339CD9-8712-40B8-A62E-73FEE6A6AA77

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans

@en

P2093

Kelly SL

http://www.w3.org/2001/XMLSchema#string

Manning NJ

http://www.w3.org/2001/XMLSchema#string

Rinaldi MG

http://www.w3.org/2001/XMLSchema#string

Taylor M

http://www.w3.org/2001/XMLSchema#string

Venkateswarlu K

http://www.w3.org/2001/XMLSchema#string

P2860

Amphotericin B: 30 years of clinical experience.

Biochemical basis for the activity and selectivity of oral antifungal drugs.

Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Biochemical approaches to selective antifungal activity. Focus on azole antifungals.

Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata.

Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B.

Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans.

Nystatin-resistant mutants of yeast: alterations in sterol content.

Molecular genetic analysis of azole antifungal mode of action.

P304

748-751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.41.4.748

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

1997-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9087482

http://www.w3.org/2001/XMLSchema#string

P932

163787

http://www.w3.org/2001/XMLSchema#string